Kennedy Capital Management LLC decreased its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 3.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 346,103 shares of the company's stock after selling 12,344 shares during the period. Kennedy Capital Management LLC owned 0.43% of Verona Pharma worth $16,073,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in VRNA. GAMMA Investing LLC lifted its stake in Verona Pharma by 20.7% in the fourth quarter. GAMMA Investing LLC now owns 1,612 shares of the company's stock valued at $75,000 after buying an additional 276 shares during the last quarter. EMC Capital Management lifted its position in Verona Pharma by 3,400.0% in the 4th quarter. EMC Capital Management now owns 3,500 shares of the company's stock valued at $163,000 after purchasing an additional 3,400 shares during the last quarter. Wrapmanager Inc. acquired a new position in Verona Pharma during the 4th quarter valued at about $207,000. Transcend Capital Advisors LLC acquired a new stake in shares of Verona Pharma in the fourth quarter valued at approximately $225,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Verona Pharma during the fourth quarter valued at approximately $225,000. Institutional investors and hedge funds own 85.88% of the company's stock.
Wall Street Analyst Weigh In
Several analysts recently commented on the company. Roth Capital set a $83.00 target price on Verona Pharma in a research report on Friday, February 28th. Canaccord Genuity Group raised their price target on Verona Pharma from $44.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday, February 12th. HC Wainwright upped their price objective on shares of Verona Pharma from $60.00 to $75.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Roth Mkm began coverage on shares of Verona Pharma in a research report on Friday, January 10th. They issued a "buy" rating and a $68.00 target price for the company. Finally, Wells Fargo & Company boosted their price target on shares of Verona Pharma from $74.00 to $93.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $69.14.
View Our Latest Report on Verona Pharma
Verona Pharma Price Performance
NASDAQ VRNA traded up $0.65 on Tuesday, reaching $58.46. The company's stock had a trading volume of 212,409 shares, compared to its average volume of 1,204,598. Verona Pharma plc has a twelve month low of $11.39 and a twelve month high of $70.40. The company has a debt-to-equity ratio of 0.93, a quick ratio of 12.88 and a current ratio of 13.03. The firm's 50 day moving average is $62.53 and its two-hundred day moving average is $48.90. The stock has a market cap of $4.72 billion, a PE ratio of -30.45 and a beta of 0.16.
Insider Buying and Selling
In other Verona Pharma news, insider Kathleen A. Rickard sold 79,264 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $8.35, for a total value of $661,854.40. Following the transaction, the insider now owns 2,608,976 shares of the company's stock, valued at approximately $21,784,949.60. This represents a 2.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.80% of the company's stock.
Verona Pharma Profile
(
Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Featured Articles
Before you consider Verona Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma wasn't on the list.
While Verona Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
